Clariant has presented key elements of its profitable growth strategy on the occasion of the Capital Markets & Media Day 2012 on 21/22 June.
The event in Munich, Germany, highlighted some of the many growth opportunities in Clariant’s portfolio. A visit to the state-of-the-art catalyst facility underlined the advantages of having R&D to scale-up and production under one roof. The potential of Biotech expertise was explored through a visit to Clariant’s Biotech center in Munich. This R&D facility includes enzyme and micro-organism optimization, protein engineering, Ultra-High-Throughput screening and pilot plants.
The site visits were completed with a series of presentations. In order to achieve its 2015 targets, Clariant needs to make considerable progress in all four of the strategic directions defined. Within the existing business units, a further profitability increase is planned through Performance Management and Functional Excellence measures. Successful innovations will generate new growth opportunities. In addition, increased market shares in emerging markets such as China, India and Brazil will further boost profitable growth.
An active portfolio management will play an important role on the path to a sustainably profitable company. They are an important pre-requisite for reaching our targets by 2015. At that point, a newly aligned Clariant will be even more profitable and will generate more than 70% of its sales from non-cyclical business units. The acquisition of Süd-Chemie marked an important first milestone in this process. We will continue this success story in the next years.
In a nutshell - the profitable growth strategy will fundamentally change the Group in the next few years and create an even more profitable Specialty Chemicals company than that of today.
Contact me
